www. iscor t .org . i l

Scientific Program

08.01.2019 - 12.01.2019, Eilat, Israel

The Annual Meeting of The Israeli Societyfor Clinical Oncology and Radiation Therapy

ISCORT wishes to express its gratitude to the following companies for their support of the 19th ISCORT Annual Meeting:

Platinum Sponsor Roche

Gold Sponsor BMS MSD

Silver Sponsor Astellas Astrazeneca Boehringer Ingelheim Eli Lilly ISI Novartis Pfizer Rafa

Bronze Sponsor AbbVie Assuta Bayer Bolpharma Dexcel Pharma Isotopia Medison Merck Nanostring Neopharm Oncotest-Teva Perrigo Sanofi Takeda I.M. Knasim Ltd.

Organizing Company החברה המארגנת

א.מ. כנסים בע"מ

נשיא הכנס:

פרופ׳ סלומון שטמר

מזכירת הכנס:

ד״ר ולריה סמניסטי

יו"ר הרדיותרפיה:

פרופ׳ בן קורן

President:Salomon M. Stemmer, MD

Secretory:Valeria Semenysty, MD

Radiation Oncology Co-Chair:Ben W. Corn, MD

Organizing Committeeהוועדה המארגנת ISCORT 19

Chairman: Michal Lotem, MDAaron Allen, MDNoam Asna, MDJair Bar, MD PhDYonathan Cohen, MD PhDBen W. Corn, MDElla Evron, MDDaniela Katz, MDGal Markel, MD PhDInna Ospovat, MD Avivit Peer, MDRuth Perets, MD PhDRaphael Pfeffer, MDKeren Rouvinov, MDKaterina Shulman, MD Amir Sonnenblick, MD Marc Wygoda, MDAlona Zer, MDAviad Zik, MD

Scientific Committee ISCORT 19הוועדה המדעית

יו"ר: פרופ׳ מיכל לוטם

ד"ר אהרון אלון

ד"ר נועם אסנה

ד"ר יאיר בר

ד"ר יהונתן כהן

פרופ׳ בן קורן

ד"ר אלה עברון

ד"ר דניאלה כץ

פרופ׳ גל מרקל

ד"ר אינה אוספובט

ד"ר אביבית פאר

ד"ר רות פרץ

ד"ר רפאל פפר

ד"ר קרן רובינוב

ד"ר יקטרינה שולמן

ד"ר אמיר זוננבליק

ד"ר מרק ויגודה

ד"ר אלונה זר

ד"ר אביעד זיק

Shalom,Salomon M Stemmer, MDPresident Ben W. Corn, MDRadiation Oncology Co-Chair

Michal Lotem, MDHead of Scientific CommitteeValerie Semenisty, MDSecretory

חברים נכבדים,קלינית לאונקולוגיה הישראלי האיגוד לכנס השנתי של ברוכים הבאים

ורדיותרפיה )ISCORT 19th( המתקיים באילת ב- 12-8 בינואר 2019.הכנס השנתי של ISCORT מארח את מרבית הצוותים המעורבים ועוסקים בטיפול ובמחקר במחלות הסרטן. כולנו עמלים יומם וליל במטרה לטייב את הטיפול על כל מרכיביו, שיפור בהישרדות והקטנת תופעות הלוואי, במטרה להאריך את החיים ולשפר את איכות החיים של החולה, משפחתו והחברה כולה. במקביל אנו עמלים על הוראה נטולת הטיות והנגשת הטיפול המיטבי

לכל תושבי מדינת ישראל.בכנס שאירגנו לשנה זו תועלנה מספר סוגיות בנוגע למורכבות הטיפול בחולה

במאה ה-21.בשנים האחרונות אנו חווים התפוצצות מידע עם גילוי יותר תרופות "מוכוונות ונסיון כן וחסרונותיה, יתרונותיה מטרה", הפעלת המערכת החיסונית על להקטנת תחלואה. חדשנות מביאה לשינוי תפיסה לגבי טיפולים מוכווני מטרה ולא מוכווני האיבר שבו נוצר הגידול. התובנות החדשות, בין השאר של גופים

רגולטורים, הביאו גם לקיצור בזמנים להבאת טכנולוגיות חדשות לחולים.אנו חסרים עדיין תובנות רחבות יותר לגבי יחסי גומלין בין מחלה לחולה, בין גוף לנפש, מגדר ומגזר, התנהגות ואמונה. חדשנות ואינטרגרציה עשויים לשפר את הטיפול בחולים שלנו. הרפואה והבריאות חשובים ביותר בחיי הפרט והחברה. מכאן חובתינו להתיחס גם למרכיבים כלכליים של הטיפול. על כן יכלול הכנס השנה מושבים קצרים בנושא של "ערך הטיפול בסרטן" מנקודת מבט כלכלית.פתחנו מושבים של "פגוש את המומחה" המיועדים למתמחים ולמומחים יוכלו לדון במקרים בעייתיים עם האורחים הבינלאומיים צעירים, שבהם

שמגיעים לכנס.אנו מודים לכל העושים במלאכה להצלחת הכנס, ולחברי הוועדה המדעית, על

עבודתם לבחירת מיטב התקצירים שיוצגו בכנס.בינלאומי, כל ההרצאות כנס ,ESMO-ל והכנס מסונף היות נזכיר, לסיום

והמושבים יתנהלו בשפה האנגלית.

מאחלים לכולנו כנס פורה, מוצלח ומהנה,

שלום,

Dear friends and colleagues,Welcome to the 19th annual meeting of the Israel Society for Clinical Oncology and Radiotherapy )ISCORT( to be held in Eilat on January 8-12, 2019.The ISCORT annual meeting hosts the majority of Israeli teams in the field. All of us are dedicated to the treatment of cancer patients, enhancing care, improving outcome and reducing toxicity. We strive to improve the quality of life for the patient, family members and society. We seek to promote unbiased education and improve access to optimal and affordable cancer care.This year’s program emphasizes the complexity of cancer care in the 21st century.During the last years we have witnessed the rapid unfolding of cancer research, targeted therapy, as well as the advantages and limitations of the powerful immune system. Innovations in most areas of treatment have led to an agnostic approach with faster and more comprehensive drug approval by regulatory agencies. We are still on a quest for the ideal treatment, tailored to the specific human being with his/her unique physiology, psychology, ethnicity, behavior and belief. Novelty and integration will surely bring our patients to the best possible outcome. Yet all novel approaches must be placed in a framework of value to the individual patient as well as society. Therefore, we will have short sessions that will provide such context.For the residents and young faculty we launched a new format for ISCORT, “Meet the Professor”, where participants are encouraged to present challenging cases or to pose professional dilemmas to our distinguished guests.We thank all members who participated in the organization of the meeting and scientific committee members for selecting the best abstracts to be shared by us.

Looking forward to a great conference,

פרופ׳ מיכל לוטםיו"ר ועדה מדעית

ד"ר ולריה סמניסטימזכירה

פרופ׳ סלומון שטמרנשיא

פרופ׳ בן קורןיו"ר הרדיותרפיה

Tuesday, January 8, 2019

17:00–19:30 Opening SessionModerator: Valeria Semenisty, MD Rambam Medical Center Haifa, Israel

17:00-17:20 Welcome Salomon M. Stemmer, MD Davidoff Center, Rabin Medical Center, Petach

Tikva, Israel Wilmush Mermershtain, MD ISCORT

17:20-17:30 Resident Recognition Award Mrs. Miri Ziv, CEO Israel Cancer Association, Givatayim, Israel

17:30-18:10 Best ISCORT Abstract Awards Moderator: Michal Lotem, MD Hadassah Medical Center

Jerusalem, Israel Neoadjuvant pembrolizumab (Pembro) for early

stage non-small cell lung cancer (NSCLC) – initial report of a phase I study, MK3475-223

Jair Bar, MD PhD Sheba Medical Center, Ramat-Gan, Israel Prophylactic irradiation to the contralateral

breast for BRCA mutation carriers with early mammary cancer

Ella Evron, MD Kaplan Medical Center, Rehovot, Israel A functional variant of the estrogen receptor: A

potential novel driver of pancreatic cancer Ido Wolf, MD Sourasky Medical Center, Tel-Aviv, Israel Discussion and perspectives Michal Lotem, MD Hadassah Medical Center, Jerusalem, Israel

18:10-18:50 Keynote LectureModerator: Gil Bar-Sela, MD Haemek Medical Center, Afula, Israel Moving from precision medicine to next

generation healthcare Joel Dudley, PhD Associate Professor of Genetics and Genomic

Sciences Director of the Institute for Next Generation

Healthcare Mount Sinai Endowed Professor of Biomedical

Data Science Icahn School of Medicine at Mount Sinai Executive Vice President for Precision Health Mount Sinai Health System New York, USA Supported by ISCORT and MSD18:50-19:30 Keynote LectureModerator: Nir Peled, MD PhD Soroka Medical Center, Beer Sheva, Israel Clinical trials, personalized medicine and

relationships with pharma: Time for reflection? Ian Tanock, MD Emeritus professor of Medical Oncology and

Medical Biophysics Princess Margaret Cancer Centre and university of

Toronto, Canada Supported by ISCORT

19:30 Dinner

Wednesday, January 9, 2019

07:30-08:15 Meet the Professor Lung Cancer Tarshish B Hall Moderators: Mor Moshkovich, MD Rambam Medical Center, Haifa, Israel Abed Agbarya, MD Bnai Zion Medical Center, Haifa, Israel Francis Shepherd, MD Department of Medicine at the University of

Toronto, Canada Supported by MSD Prostate Cancer Tarshish A Hall Moderators: Noa Shani Shrem, MD Soroka Medical Center, Beer Sheva, Israel David Sarid, MD Sourasky Medical Center, Tel-Aviv, Israel Johann de-Bono, MD The Institute of Cancer Research and The Royal

Marsden NHS Foundation Trust, London, England Supported by ASTELLASGenito-Urinary Malignancies – General Session08:20-09:00 Keynote LectureModerators: Eliezer Rosenbaum, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel Avivit Peer, MD Rambam Medical Center, Haifa, Israel

Understanding the pathway in prostate cancer, present and future

Johann de-Bono, MD The Institute of Cancer Research and The Royal

Marsden NHS Foundation Trust, London, England Supported by Astellas and Janssen09:00-09:25 Sponsored LectureModerators: Victoria Neiman, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel Keren Rouvinov, MD Soroka Medical Center, Beer Sheva, Israel 2019 NHB - New treatment paradigm in RCC Daniel Keizman, MD Meir Medical Center, Kfar Saba, Israel Supported by BMS09:25-09:35 Value of Cancer CareModerator: Raya Leibowits, MD PhD ISCORT Basket Committee Daniel Goldstein, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel09:35-10:15 Tumor Board: Urological MalignanciesModerator: Avishay Sella, MD Shamir )Asaf Harofe( Medical Center, Tzrifin, IsraelPanel: Johann de-Bono, MD The Institute of Cancer Research and The Royal

Marsden NHS Foundation Trust, London, England Wilmush Mermershtein, MD Soroka Medical Center, Beer Sheva, Israel Raanan Berger, MD PhD Sheba Medical Center, Ramat-Gan, Israel

Avivit Peer, MD Rambam Medical Center, Haifa, Israel Eliezer Rosenbaum, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel10:15-10:30 Coffee Break10:30-11:10 Original Abstracts: GU and Melanoma Moderators: Maya Kolin, MD Rambam Medical Center, Haifa, Israel Yonathan Cohen, MD PhD Hadassah Medical Center, Jerusalem, Israel Genomic analysis of urothelial cancer and

associations with treatment choice and outcome –collaborative research from the Israeli GU

oncology group Raya Leibowitz MD PhD Sheba Medical Center, Ramat-Gan, Israel Short term androgen deprivation therapy with/

without pelvic lymph node treatment added to prostate bed only salvage radiotherapy: RTOG 0534

Aron Allen, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel Ipilimumab-Nivolumab combination therapy

in metastatic melanoma patients who have progressed on previous anti PD-1 therapy

Guy Ben-Betzalel, MD Sheba Medical Center, Ramat-Gan, Israel Brain derived melanoma cells suppress expression

of key transcripts in tumor infiltrating lymphocytes as compared with melanoma from visceral metastases

Jonathan Cohen, MD PhD Hadassah Medical Center, Jerusalem, Israel

Preliminary results from microbiome-based phase I clinical trial - fecal microbiota transplantation in metastatic melanoma patients who failed immunotherapy (NCT03353402)

Gal Markel, MD PhD Sheba Medical Center, Tel Hashomer, Israel11:10-11:30 Sponsored LectureModerator: Ronen Brenner, MD Wolfson Medical Center, Bat-Yam, Israel MORPEHEUS: Novel clinical trial design for

immunotherapy combinations Julie Maltzman, MD Group Medical Director Genentech a Member of The Roche Group, CA, USA Supported by Roche 11:30-12:10 Tumor Board: Precision Oncology Moderator: Tamar Peretz, MD Hadassah Medical Center, Jerusalem, IsraelPanel: Dov Hershkovitz, MD Sourasky Medical Center, Tel-Aviv, Israel Nir Peled, MD PhD Soroka Medical Center, Beer Sheva, Israel Raanan Berger, MD PhD Sheba Medical Center, Ramat-Gan, Israel Eitan Rubin, PhD Senior Researcher Ben Gurion University, Beer Sheva, Israel Doron Lipson, PHD VP Research & Early Development Foundation Medicine Inc., Cambridge, USA Supported by Roche12:10-13:00 Lunch

Lung Cancer - General Session13:00-13:40 Keynote LectureModerator: Alona Zer, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel Understanding the pathway in lung cancer Frances Shepherd, MD Department of Medicine at the University of

Toronto, Canada Supported by MSD 13:40-14:05 Sponsored LectureModerator: Yulia Dudnik, MD Soroka Medical Center, Beer Sheva, Israel Stage III non small cell lung cancer, new

paradigm Scott J. Antonia, MD PhD Thoracic Oncology Department, H.Lee Moffitt

Cancer Center and Research Institute, Tampa Florida , USA

Supported by Astra Zeneca14:05-14:25 Sponsored LectureModerator: Hovav Nechushtan, MD PhD Hadassah Medical Center, Jerusalem, Israel Next generation targeted therapies: Sequencing

challenges or best drug first? Maya Gottfried, MD Meir Medical Center, Kfar Saba, Israel Supported by Astra Zeneca and Takeda14:25-15:05 Original Abstracts: Lung and Basic Science Moderators: Elizabeth Dudnik, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel Mira Wollner, MD Rambam Medical Center, Haifa, Israel

The association between proton pump inhibitors use and lung cancer risk: A nested case-control study

Hadas Dresler, MD Meir Medical Center, Kfar Saba, Israel Osimertinib for patients with EGFR-positive

advanced non-small cell lung cancer and asymptomatic brain metastasis: preliminary analysis of an open label two arm phase II study Nir Peled, MD PhD

Soroka Medical Center, Beer Sheva, Israel A single MAPK/Erk phosphorylation site dictates

distinct functions of highly homologous co-repressors

Hovav Nechushtan, MD PhD Hadassah Medical Center, Jerusalem, Israel EF hand domain family member D2 is required

for T cell cytotoxicity Amir Onn, MD Sheba Medical Center, Ramat-Gan, Israel15:05-15:45 Tumor Board: Lung MalignanciesModerator: Jair Bar, MD PhD Sheba Medical Center, Ramat-Gan,IsraelPanel: Maya Gottfried, MD Meir Medical Center, Kfar Saba, Israel Damian Urban, MD Sheba Medical Center, Ramat-Gan Israel Frances Shepherd, MD Department of Medicine, Toronto University

Canada Uzi Izhar, MD Hadassah Medical Center, Jerusalem, Israel Raphael Pfeffer, MD Assuta Medical Center, Tel-Aviv, Israel Supported by BI

15:45-16:00 Coffee Break16:00-16:25 Sponsored LectureModerator: Noam Asna, MD Barzilai Medical Center, Ashquelon, Israel The evolving treatment landscape in SCLC Barlessi Fabrice, MD PhD Professor of Medicine, University of Aix Marseille

and head of the Multidisciplinary Oncology and Therapeutic Innovations Department at Assistance Publique Hôpitaux de Marseille, France

Supported by Roche16:25-16:35 Value of Cancer CareModerator: Katerina Shulman, MD ISCORT Basket Committee Daniel Goldstein, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel16:35-17:05 Keynote LectureModerator: Ben W. Corn Shaare Zedek Medical Center, Jerusalem, Israel Current thinking in the design of immuno-

oncology and radiotherapy trials Adam P. Dicker, MD FASTRO Professor & Chair, Department of Radiation

Oncology Director, Scholarly Inquiry Program in Digital

Health & Data Science, Sidney Kimmel Medical College and Cancer Center, Philadelphia, USA

Supported by ISCORT

17:05-17:45 Tumor Board: Brain MetastasisModerators: Shlomit Yust, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel Dror Limon, MD Sourasky Medical Center, Tel-Aviv, IsraelPanel: Mor Moskovitz, MD Rambam Medical Center, Haifa, Israel Yosef Laviv, MD Rabin Medical Center, Petach Tikva, Israel Orit Kaidar-Person, MD Rambam Medical Center, Haifa, Israel19:00 Dinner

07:30-08:15 Meet the Professor Breast Malignancies Tarshish A Hall Moderators: Ayelet Shai, MD Galilee Medical Center, Nahariya, Israel Bella Kaufman, MD Sheba Medical Center, Ramat-Gan, Israel Karen Gelmon, MD Professor of Medicine University of British

Columbia, Medical Oncologist BCCancer, Canada Supported by Astra Zeneca and MSD Radiotherapy Fiesta HallModerators: Salem Billan, MD Rambam Medical Center, Haifa, Israel Raphael Yechieli, MD University of Miami and Sylvester Comprehensive

Cancer Center, USA Adam Dicker, MD Professor & Chair, Department of Radiation

Oncology Director, Scholarly Inquiry Program in Digital

Health & Data Science Sidney Kimmel Medical College and Cancer

Center, Philadelphia, PA, USA How to Read a Paper Tarshish B HallModerators: Alberto Gabizon, MD Shaare Zedek Medical Center, Jerusalem, Israel Einav Gal Yam, MD PhD Sheba Medical Center, Ramat-Gan, Israel

Thursday, January 10, 2019 Ian Tannock, MD Emeritus professor of Medical Oncology and

Medical Biophysics, Princess Margaret Cancer Centre and University of Toronto, Canada

08:20-08:40 Case Reports and DiscussionModerator andDiscusssant: Ruth Perets, MD PhD Rambam Medical Center, Haifa, Israel Tumor lysis syndrome (TLS) in patient with

metastatic non-small cell lung carcinoma (mNSCLC) after a single dose of atezolizumab

Shira Sherman, MD Davidoff Center, Rabin Medical Center, Petach

Tikva, Israel Photofrin II as a radiosensitizer in cervix cancer Noam Asna, MD Barzilai Medical Center, Ashkelon, IsraelGastro Intestinal Malignancies – General Session08:40-09:10 Keynote LectureModerator: Nirit Yarom, MD Shamir )Asaf Harofe( Medical

Center, Tzrifin, Israel Understanding the pathway GI tumors Dan Aderka, MD Sheba Medical Center Ramat-Gan, Israel09:10-09:45 Keynote LectureModerator: Ephraim Idelevich, MD Kaplan Medical Center

Rehovot, Israel Present and future of systemic treatment of

hepatocellular carcinoma Peter R. Galle, Univ-Prof Dr Chairman - First Department of Internal

Medicine, University Medical Center Mainz, Germany Supported by ISCORT

09:45-10:10 Tumor board - Advanced Hepatocellular Carcinoma

Moderator: Ravit Geva, MD Sourasky Medical Center, Tel-Aviv, IsraelPanel: Peter R. Galle, Univ-Prof Dr Chairman - First Department of Internal

Medicine, University Medical Center Mainz, Germany Oren Shibolet, MD Sourasky Medical Center, Tel-Aviv, Israel Allan-Isaac Bloom, MD Hadassah Medical Center, Jerusalem, Israel Supported by Roche and ISCORT10:10-10:40 Is There a Role for Surgery in Advanced GI

Malignancies?Moderator: Ayala Hubert, MD Hadassah Medical Center

Jerusalem, Israel Pro: Izhak Avital, MD Soroka Medical Center Beer Sheva, Israel Con: Baruch Brenner, MD Davidoff Center Rabin Medical Center, Petach Tikva, Israel 10:40-10:55 Coffee Break10:55-11:35 Tumor board – Gastro Intestinal MalignanciesModerator: Irit Ben Aharon, MD PhD Rambam Medical Center, Haifa, Israel Panel: Talia Golan, MD Sheba Medical Center, Ramat-Gan, Israel Sharon Peles, MD Sourasky Medical Center, Tel-Aviv, Israel Eli Sapir, MD Assuta Medical Center, Ashdod, Israel

Riad Haddad, MD Bnai Zion Medical Center Haifa, Israel Supported by Eli Lilly11:35-12:20 Original Abstracts: GI Malignancies Moderators: Sofia Man, MD Soroka Medical Center, Beer Sheva, Israel Ofer Purim, MD Assuta Medical Center, Ashdod, Israel Benefit of oxaliplatin in stage III colon cancer

according to IDEA risk groups – analysis of MOSAIC and C-07 trials

Ofer Margalit, MD Sheba Medical Center, Ramat-Gan, Israel Postoperative chemoradiotherapy in patients

with locally advanced gastric cancer with poor pathologic response to neoadjuvant chemotherapy

Ron Lewin, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel Regorafenib treatment for patients with

hepatocellular carcinoma who progressed on sorafenib - A cost-effectiveness analysis

Daniel Goldstein, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel The role of genomic alterations as drivers of

liver-specific metastasis formation in pancreatic ductal adenocarcinoma (PDAC) cancer

Ido Wolf, MD Sourasky Medical Center, Tel-Aviv, Israel ATM as a biomarker for homologous

recombination repair deficiency in pancreatic ductal adenocarcinoma

Tamar Beller, MD Sheba Medical Center, Ramat-Gan, Israel

12:20-13:00 Lunch13:00-14:00 Conference will reconvene at Tarshish Hall 1st FloorModerator: Salomon M. Stemmer, MD Davidoff Center Rabin Medical Center, Petach Tikva, Israel Innovation and collaborationBreast Cancer – General Session14:00-14:40 Keynote LectureModerator: Tamar Safra, MD Sourasky Medical Center, Tel-Aviv, Israel Finding our way through the pathways of breast

cancer Karen A Gelmon, MD FRCPC Professor of Medicine University of British

Columbia Medical Oncologist BCCancer, Canada Chair UBC/BCC Research Ethics Board Supported by Astra Zeneca and MSD14:40-15:10 Sponsored LectureModerator: Ekarerina Senatsky, MD Lin Medical Center, Haifa, Israel Update in treatment of advanced HR-positive

HER2-negative breast cancer including position of CDK 4-6

Miguel Martin, MD PhD Professor of Medicine, Head Medical Oncology

Service, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid

Spain Supported by Eli Lilly15:10-15:20 Value of Cancer Care in Breast Cancer Moderator: Rinat Yerushalmi, MD ISCORT Basket Committee Nathan Cherny, MD Shaare Zedek Medical Center, Jerusalem, Israel

15:20-16:00 Tumor Board: Breast CancerModerator: Noa Efrat Ben-Baruch, MD Kaplan Medical Center, Rehovot, IsraelPanel: Rinat Yerushalmi, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel Tamar Peretz, MD Hadassah Medical Center, Jerusalem, Israel Bella Kaufman, MD Sheba Medical Center, Ramat-Gan, Israel Amir Sonnenblick, MD Sourasky Medical Center, Tel-Aviv, Israel Dov Zippel, MD Sheba Medical Center, Ramat-Gan, Israel Supported by Roche16:00-16:15 Coffee Break16:15-16:40 Sponsored LectureModerator: Ella Evron, MD Kaplan Medical Center, Rehovot, Israel Small steps, big impact – Rethinking outcome

measures in high risk breast cancer Shani Paluch-Shimon, MD Shaare Zedek Medical Center, Jerusalem, Israel Supported by Roche16:40-17:05 Sponsored LectureModerator: Jamal Zidan, MD Ziv Medical Center, Safed, Israel New horizons in clinical trials Chris Boshoff Senior Vice-President, Head Immuno-Oncology,

Early Development and Translational Oncology, Pfizer

Supported by Pfizer

17:05-17:55 Original Abstracts: Breast Malignancies Moderators: Beatrice Uziely, MD Hadassah Medical Center, Jerusalem, Israel Larissa Rivo, MD Assuta Hospital, Ashdod, Israel Partial compared to whole breast irradiation for

early stage breast cancer: A systematic review and meta-analysis

Yasmin Korzets Ceder, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel Pregnancy after breast cancer diagnosis in

BRCA1\2 mutation carriers Albert Grinshpun, MD Hadassah Medical Center, Jerusalem, Israel The rate of the recurrent MSH6 mutations in

Ashkenazi Jewish breast cancer patients Rinat Bernstein Molho, MD Sourasky Medical Center, Tel-Aviv, Israel Toxicity of extended adjuvant aromatase

inhibitors therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis

Hadar Goldvaser, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel Is prophylactic breast surgery indicated in BRCA

mutation carriers following diagnosis of ovarian cancer?

Barliz Waissengrin, MD Sourasky Medical Center, Tel-Aviv, Israel19:00 Dinner

Immune Oncology 08:30-10:05 Keynote lecture Moderators: Michal Lotem, MD Hadassah Medical Center, Jerusalem, Israel Gal Markel, MD PhD Sheba Medical Center, Ramat-Gan, Israel

08:30-08:35 Introduction Michal Lotem, MD Hadassah Medical Center, Jerusalem, Israel 08:35-09:05 Immune checkpoint inhibitors in melanoma and

other cancers - a review John Haanen Professor of Translational Immunotherapy of

Cancer, Leiden University Medical Center The Netherlands Supported by MSD09:05-09:35 Tumor neo-antigens and T cell recognition Yardena Samuels Director, the EKARD Institute for Cancer Diagnosis

Research, Department of Molecular Cell Biology, The Weizmann Institute of Science

Rehovot, Israel09:35-10:05 Immunotherapy beyond melanoma Dmitriy Zamarin, MD Gynecologic Medical Oncology,

Immunotherapeutics, Memorial Sloan-Kettering Cancer Center, New York, USA

Supported by ISCORT

Friday, January 11, 2019

10:05-10:45 Sponsored LectureModerator: Alexander Yaacobson, MD Soroka Medical Center, Beer Sheva, Israel New approaches in the treatment of local and

advanced melanoma Jacob Schachter, MD Sheba Medical Center, Ramat-Gan, Israel Michal Lotem, MD Hadassah Medical Center, Jerusalem, Israel Supported by BMS10:45-11:00 Coffee Break11:00-11:30 Tumor Board: MelanomaModerator: Ronni Shapira, MD Sheba Medical Center, Ramat-Gan, IsraelPanel: Gil Bar-Sela, MD Haemek Medical Center, Afula, Israel Ronnen Brenner, MD Wolfson Medical Center, Holon, Israel Olga Vornicova, MD Rambam Medical Center, Haifa, Israel Dov Zipel, MD Sheba Medical Center, Ramat-Gan, Israel Supported by NOVARTIS11:30-11:50 Sponsored LectureModerator: Raya Leibowitz, MD PhD Sheba Medical Center, Ramat-Gan, Israel Are we ready to offer a truly pan-tumor approach

to therapy? Ido Wolf, MD Sourasky Medical Center, Tel-Aviv, Israel Supported by Roche

11:50-12:30 Proposals and Follow-Up From Previous Years Grants Reports

Moderators: Valeria Semenisty, MD Rambam Medical Center, Haifa, Israel Michal Lotem, MD Hadassah Medical Center, Jerusalem, Israel Liquid biopsy of tumor microbiome Albert Grinshpun, MD Hadassah Medical Center, Jerusalem, Israel Interleukin-13 Receptor α1: A novel molecular

target to prevent radiation induced heart disease Uri Amit, MD Sheba Medical Center, Ramat-Gan, Israel12:30 Closing Remarks12:45 Lunch13:30-14:30 ISCORT Forum Meeting

Radiation Oncology Program

07:30-08:15 Meet the Professor Fiesta Hall RadiotherapyModerators: Salem Billan, MD Rambam Medical Center, Haifa, Israel Raphael Yechieli, MD University of Miami and Sylvester Comprehensive

Cancer Center Florida, USA Adam Dicker, MD Professor & Chair, Department of Radiation

Oncology Director, Scholarly Inquiry Program in Digital

Health & Data Science Sidney Kimmel Medical College and Cancer

Center Philadelphia, PA, USA

Wednesday, January 9, 2019

16:35-17:05 Keynote Lecture Lecture would be held in the main conference hallModerator: Ben W. Corn, MD Shaare Zedek, Medical Center, Jerusalem, Israel Current thinking in the design of immuno-

oncology and radiotherapy trials Adam P. Dicker, MD FASTRO Professor & Chair, Department of Radiation

Oncology Director, Scholarly Inquiry Program in Digital

Health & Data Science, Sidney Kimmel Medical College and Cancer Center, Philadelphia, PA, USA

Supported by ISCORT

Thursday, January 10, 2019

08:30-09:50 Clinical Abstracts Moderators: Eliahu Gez, MD Ziv Medical Center, Safed, Israel Salem Billan, MD Rambam Medical Center, Haifa, Israel Adaptive IMRT planning improves pharyngeal

constrictor sparing for oropharyngeal cancer Dror Limon, MD Sourasky Medical Center, Tel-Aviv, Israel CPAP improves the anatomy and dosimetry

of patients undergoing breath-hold motion management for thoracic SBRT

Igor Sadetskii, MD Sheba Medical Center, Ramat-Gan, Israel Modern radiotherapy with or without androgen

deprivation therapy in intermediate-risk prostate cancer

Uri Amit, MD Sheba Medical Center, Ramat-Gan, Israel Gastric fundus irradiation does not increase

risk of postoperative anastomotic leakage in esophageal cancer

Noga Kurman, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel Adjuvant irradiation sandwiched between 6

cycles of carboplatin and paclitaxel for FIGO stage III endometrial adenocarcinoma

Nicola Nasser, MD PhD Montefiore Medical Center, Albert Einstein College

of Medicine, New York, USA The outcome of concomitant chemoradiotherapy

for the treatment of nasopharyngeal carcinoma in the elderly population

Orly Yariv, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel

The effect of surgery to radiation interval on loco-regional recurrence and survival in patients receiving post-mastectomy radiation treatments

Adaya Rosenthal, MD Sheba Medical Center, Ramat-Gan, Israel09:55-10:30 Physics AbstractsModerator: Rachel Bar Deroma, PhD Rambam Medical Center, Haifa, Israel Development of X-ray lens for low energy

radiotherapy & radiosurgery. Dror Alezra, PhD Sheba Medical Center, Ramat-Gan, Israel Do it, fuse it or lose it: On the benefits of PET CT

simulation Alona Rosenbaum, PhD Ziv Medical Center, Safed, Israel SRS spine plans: Comparing elements & eclipse

simulations to real measures Noam Weizman, MSc Hadassah Medical Center, Jerusalem, Israel10:40-10:55 Coffee Break10:55-11:20 Sponsored LectureModerator: Raphael Pfeffer, MD Assuta Medical Center, Tel-Aviv, Israel Daphne Levin, PhD Assuta Medical Center, Tel-Aviv, Israel Real time image-guided RT: From 2D to 4D. Will

the MR Linac change practice? Supported by Assuta Medical Center 11:20-12:05 Sponsored Lecture Proton therapy: Benefits of IMPT Zelig Tochner, MD Professor of Radiation Oncology, University of

Pennsylvania, PA, USA Supported by VARIAN

12:05-12:30 Sponsored Lecture The Elekta unity MR Linac – An overview and

update of clinical experience Joel W. Goldwein, MD Senior Vice President and Director, Medical Affairs

Elekta, Philadelphia, PA, USA Supported by Medtechnika12:30-13:15 Lunch13:30-14:15 Clinical Debate: Oligometastatic Disease Turns 25Moderator: Adam P. Dicker, MD FASTRO Professor & Chair, Department of Radiation

Oncology Director, Scholarly Inquiry Program in Digital

Health & Data Science, Sidney Kimmel Medical College and Cancer Center, Philadelphia, PA, USA

Amichay Meirowitz, MD Hadassah Medical Center, Jerusalem, Israel Tomer Charas, MD Rambam Medical Center, Haifa, Israel14:30-15:15 Revisiting the Conventional Wisdom in Non-Small

Cell Lung CancerModerator: Orit Person, MD Rambam Medical Center, Haifa, Israel Differential radiosensitivity between the lung

primary and the mediastinum Slava Soyfer, MD Sourasky Medical Center, Tel-Aviv, Israel Technological advances in the treatment of lung

cancer Sarit Appel, MD Sheba Medical Center, Ramat-Gan, Israel Integrating radiotherapy with novel biologic &

immunotherapeutic agents Aaron Allen, MD Davidoff Center, Rabin Medical Center Petach Tikva, Israel

15:30-16:00 Keynote LectureIntroduction: Zvi Symon, MD Sheba Medical Center, Ramat-Gan, Israel Teen horror: The radiation oncologist meets the

AYA population Raphael Yechieli, MD Associate Professor of Radiation Oncology,

University of Miami and Sylvester Comprehensive Cancer Center, Miami, FL, USA

16:00-16:25 Coffee Break 16:30-17:00 Sponsored LectureModerator: Maoz Ben Ayun, PhD Chaim Sheba Medical Center, Ramat-Gan, Israel ExacTrac Dynamic – A new dimension in surface

tracking Luisa Schuetzenmeister, MSc Product Manager ExacTrac BRAINLAB, Munich, Germany Supported by BRAINLAB17:00-17:25 Sponsored Lecture Proton therapy: A perspective on the future Nicolas Denef, MSc Product Manager, IBA Louvain-La-Neuve, Belgium17:30-18:15 Roundtable Discussion NRG & ISROG: Re-Kindling the Flames of

Research?

Moderator: Aaron Allen, MD Rabin Medical Center, Petach Tikva, IsraelPanel: Rachamim Ben-Yosef MD Rambam Medical Center, Haifa, Israel Yaacov Lawrence, MD Sheba Medical Center, Ramat-Gan, Israel Adam Dicker, MD Professor & Chair, Department of Radiation Oncology Director, Scholarly Inquiry Program in Digital Health & Data Science, Sidney Kimmel Medical College and Cancer Center, Philadelphia, PA, USA Shalom Kalinicki, MD Professor of Radiation Oncology, Albert Einstein

College of Medicine Chairman, Department of Radiation Oncology Montefiore Medical Center New York, USA

This programm was printed with the support of Roche Pharmaceuticals )Israel( Ltd.